Join Growin Stock Community!
Beta
Back to KNSA.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

KNSA Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

Kiniksa pharmaceuticals international, plc (KNSA) 2026Q1 financial report shows revenue of 214.27M USD, with a YoY growth rate of 55.51%. This outstanding figure clearly proves the company’s exceptionally strong operational momentum and significant expansion in market demand. To accurately capture Kiniksa pharmaceuticals international, plc (KNSA)’s future growth potential, investors should closely follow subsequent financial reports and key strategic movements, and deeply integrate diversified data and tools such as Growin AI Value Analysis for a comprehensive and forward-looking strategic assessment.